logo

COVID-19: Drugs in Development

Share

The COVID-19 outbreak, which started in December 2019 in Wuhan City, China, was declared a "Public Health Emergency of International Concern" by the WHO on January 30, 2020. The outbreak was characterized as a pandemic on March 11, 2020.

Currently, there are no drugs to treat COVID-19, caused by the novel coronavirus SARS-CoV-2.

Listed below are companies that are in the race to find a treatment or vaccine for the novel coronavirus.

Subscribe to RTT Intelligent Investor for FREE 7-Day Trial with complete access to COVID-19 Drugs in Development Calendar.

Company Name
Drug
Current Stage
Next Milestone
Collaboration
Last Updated
Key Capital cORP. (KCPC.OB)
COVID-19 oral pill vaccine
Laboratory testing

On Jan.18, 2021, the company announced promising safety profile and 90% reduction in virus infectivity in mammalian cells
-
-
01/20/2021
Johnson & Johnson
(JNJ)
Ad26.COV2.S Vaccine
Phase 3 trial of a two-dose regimen of Ad26.COV2.S, dubbed ENSEMBLE 2
-
UK National Institute for Health Research (NIHR)
12/31/2020
CohBar, Inc.
(CWBR)
CB5064
Preclinical model of Acute Respiratory Distress Syndrome treated with CB5064 generated positive results
-
-
12/30/2020
CureVac N.V.
(CVAC)
CVnCoV
-- Phase IIa clinical trial in Peru and Panama initiated in Sep.2020
-- Pivotal Phase 2b/3 study of CVnCoV initiated on Dec.14, 2020 in Europe and Latin America
-- phase 3 trial initiated on Dec.21, 2020 at the University Hospital Mainz
-
CEPI, Bill & Melinda Gates Foundation and Defense Advanced Research Projects Agency (DARPA)
12/30/2020
Atea Pharmaceuticals, Inc.
(AVIR)
AT-527
Phase 2 trial of AT-527 for patients hospitalized with moderate COVID-19
-
-
12/29/2020
Aerpio Pharmaceuticals, Inc.
(ARPO)
Razuprotafib for the treatment of acute respiratory distress syndrome in adult patients w
phase 2 study (I-SPY COVID Trial)
Data in 1H, 2021
Quantum Leap Healthcare Collaborative
12/29/2020
Akari Therapeutics Plc
(AKTX)
Nomacopan for COVID-19 pneumonia patients
Phase I/II study in the U.K. to determine the safety and effectiveness of multiple drugs for the treatment of COVID-19 (AGILE)
-- Initial review of UK study expected early 2021.
-- Initiation of a randomized multi-center randomized study in patients hospitalized with COVID-19 pneumonia in the U.S. planned for Q1, 2021
-
12/28/2020
Agenus Inc.
( AGEN, AGEND)
iNKT Cell Therapy
First COVID-19 patient dosed with iNKT cell therapy on Nov.2, 2020
-
-
12/28/2020

Get Full Access to latest records of COVID-19 Drugs in Development Calendar by subscribing to RTT Intelligent Investor with FREE 7-Day Trial. (No Credit Card Required)

Editors Pick
American Airlines has extended its offer to waive change fees for customers who purchase tickets for travel, until March 31 in response to lower travel demand due to the coronavirus pandemic. This means that travelers are provided additional flexibility by not asking them to pay penalties for changing the origin and destination cities. Lancaster Foods LLC has recalled certain conventional processed butternut squash items citing the potential to be contaminated with Listeria Monocytogenes, the U.S. Food and Drug Administration said. The products recalled included Autumn Medley, Butternut Squash Noodles, Butternut Squash Planks, Squash Noodle Medley, Butternut Squash Chunks, and Veggie Rice Blend in various measures. Amazon.com Inc. has offered to help the newly sworn-in US President Joe Biden with speedy delivery of Covid-19 vaccines across the United States amid the ongoing pandemic crisis. The e-commerce giant, whose majority of workers are in the frontline of the pandemic, reiterated its request to prioritize its essential workers to receive the vaccines at the earliest appropriate time.